Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.37 |
| ▸ | MYLK | Q15746 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | PRKCG | P05129 | 1/20 | 0.37 |
| ▸ | PRKCA | P17252 | 1/20 | 0.37 |
| ▸ | APEX1 | P27695 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | PRKCI | P41743 | 1/20 | 0.35 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19303918 | 0.84 | IDO1 (0.46) | MAPTGAATSHRMAPK1HTT | |
| SCHEMBL1887779 | 0.81 | MAPT (0.50) | MAPTGAATSHRMAPK1HTT | |
| SCHEMBL8250805 | 0.80 | IDO1 (0.40) | MAPTGAATSHRMAPK1HTT | |
| SCHEMBL7693226 | 0.79 | GAA (0.38) | MAPTGAATSHRMAPK1HTT | |
| SCHEMBL12016019 | 0.79 | IDO1 (0.44) | MAPTIDO1PRKCEMYLKALDH1A1 | |
| SCHEMBL19899827 | 0.79 | MAPT (0.44) | MAPTGAATSHRMAPK1HTT | |
| SCHEMBL108757 | 0.79 | MAPT (0.44) | MAPTGAATSHRMAPK1HTT | |
| SCHEMBL29354986 | 0.79 | MAPT (0.44) | MAPTGAATSHRMAPK1HTT | |
| SCHEMBL23177788 | 0.78 | IDO1 (0.39) | MAPTGAATSHRMAPK1HTT | |
| Hydrochloric Acid SCHEMBL6256039 | 0.78 | MAPT (0.42) | MAPTGAATSHRMAPK1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230374017-A1 | COMPOSITIONS AND METHODS FOR ACTIVATING PYRUVATE KINASE | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2023-11-23 | — | — | US | disclosed |
| EP-3759109-B1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AS HBV REPLICATION INHIBITORS | GILEAD SCIENCES INC (US) | 2023-08-30 | — | — | EP | disclosed |
| CN-116249531-A | Compositions and methods for activating pyruvate kinase | 密执安大学评议会 | 2023-06-09 | — | — | CN | disclosed |
| EP-4185293-A1 | COMPOSITIONS AND METHODS FOR ACTIVATING PYRUVATE KINASE | The Regents of The University of Michigan (US) | 2023-05-31 | — | — | EP | disclosed |
| US-20230148157-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-05-11 | — | — | US | disclosed |
| CN-111788204-B | Substituted pyrrolizine compounds as inhibitors of HBV replication | 吉利德科学公司 | 2023-05-05 | — | — | CN | disclosed |
| US-11420974-B2 | Substituted pyrrolizine compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2022-08-23 | — | — | US | disclosed |
| WO-2022020424-A1 | COMPOSITIONS AND METHODS FOR ACTIVATING PYRUVATE KINASE | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2022-01-27 | — | — | WO | disclosed |
| US-20210147429-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2021-05-20 | — | — | US | disclosed |
| EP-3759109-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AS HBV REPLICATION INHIBITORS | GILEAD SCIENCES, INC. (US) | 2021-01-06 | — | — | EP | disclosed |
| US-8791255-B2 | (6-oxo-1,6-dihydropyrimidin-2-yl)amide derivatives, preparation thereof and pharmaceutical use thereof as AKT(PKB) phosphorylation inhibitors | SANOFI (FR) | 2014-07-29 | — | — | US | disclosed |
| US-8791255-B2 | (6-oxo-1,6-dihydropyrimidin-2-yl)amide derivatives, preparation thereof and pharmaceutical use thereof as AKT(PKB) phosphorylation inhibitors | SANOFI (FR) | 2014-07-29 | — | — | US | disclosed |
| EP-2448927-B1 | NOVEL (6-OXO-1, 6-DIHYDRO-PYRIMIDIN-2-YL)-AMIDE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF AS AKT PHOSPHORYLATION INHIBITORS | SANOFI SA (FR) | 2014-03-12 | — | — | EP | disclosed |
| EP-2448927-B1 | NOVEL (6-OXO-1, 6-DIHYDRO-PYRIMIDIN-2-YL)-AMIDE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF AS AKT PHOSPHORYLATION INHIBITORS | SANOFI SA (FR) | 2014-03-12 | — | — | EP | disclosed |
| US-20120270867-A1 | NOVEL (6-OXO-1,6-DIHYDROPYRIMIDIN-2-YL)AMIDE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF AS AKT(PKB) PHOSPHORYLATION INHIBITORS | SANOFI (FR) | 2012-10-25 | — | — | US | disclosed |
| US-20120270867-A1 | NOVEL (6-OXO-1,6-DIHYDROPYRIMIDIN-2-YL)AMIDE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF AS AKT(PKB) PHOSPHORYLATION INHIBITORS | SANOFI (FR) | 2012-10-25 | — | — | US | disclosed |
| US-20120270867-A1 | NOVEL (6-OXO-1,6-DIHYDROPYRIMIDIN-2-YL)AMIDE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF AS AKT(PKB) PHOSPHORYLATION INHIBITORS | SANOFI (FR) | 2012-10-25 | — | — | US | disclosed |
| EP-2448927-A1 | NOVEL (6-OXO-1, 6-DIHYDRO-PYRIMIDIN-2-YL)-AMIDE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF AS AKT(PKB) PHOSPHORYLATION INHIBITORS | SANOFI (FR) | 2012-05-09 | — | — | EP | disclosed |
| WO-2011001114-A1 | NOVEL (6-OXO-1, 6-DIHYDRO-PYRIMIDIN-2-YL)-AMIDE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF AS AKT(PKB) PHOSPHORYLATION INHIBITORS | SANOFI-AVENTIS (FR) | 2011-01-06 | — | — | WO | disclosed |
| WO-2011001114-A1 | NOVEL (6-OXO-1, 6-DIHYDRO-PYRIMIDIN-2-YL)-AMIDE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF AS AKT(PKB) PHOSPHORYLATION INHIBITORS | SANOFI-AVENTIS (FR) | 2011-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210147429-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | HMBS, DHFR, HCCS | MAPT 3713/4885GAA 2701/4885TSHR 4242/4885 |
| US-20120270867-A1 | NOVEL (6-OXO-1,6-DIHYDROPYRIMIDIN-2-YL)AMIDE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF AS AKT(PKB) PHOSPHORYLATION INHIBITORS | AKT1, AKT2, MTOR | MAPT 3820/4885GAA 1036/4885TSHR 870/4885 |
| US-20230148157-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | HMBS, DHFR, HCCS | MAPT 3713/4885GAA 2701/4885TSHR 4242/4885 |
| US-11420974-B2 | Substituted pyrrolizine compounds and uses thereof | HMBS, DHFR, HCCS | MAPT 3713/4885GAA 2701/4885TSHR 4242/4885 |
| US-20230374017-A1 | COMPOSITIONS AND METHODS FOR ACTIVATING PYRUVATE KINASE | PCK1, PDK2, PDK1 | MAPT 2067/4885GAA 546/4885TSHR 3270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.